Summary
Twenty-two patients, aged 16 to 67, who had malignant gliomas after surgical resection were treated with carmustine and cisplatin intravenous infusion before, during, and after radiotherapy. All patients had subtotal or total resection, or biopsy as the initial procedure. Twenty-one patients who had at least 2 cycles of chemotherapy and finished the whole course of radiotherapy were considered to be evaluable for responses. Among them, 5 had glioblastoma multiforme, 16 had anaplastic astrocytoma. The median time to tumor progression was 35 weeks (range 12–130 weeks) and median survival time was 66 weeks (range 10–156 weeks). Early progression occurred more frequently in patients with biopsy only and subtotal resection, and in patients with glioblastoma than in those with anaplastic astrocytoma. This combined modality treatment program was associated with reversible hematologic toxicity which was severe in 2 patients, and with ototoxicity in 1 patient, nephrotoxicity in 2 patients. Combination of carmustine and cisplatin with cranial irradiation for malignant gliomas is moderately toxic and appears to offer no obvious survival advantage compared with radiation therapy plus BCNU alone.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anderson AP: Post-operative irradiation of glioblastomas. Results in a randomised series. Acta Radiol 17: 475–484, 1978
Kristiansen K, Hagen S, Kollevoid T, Torvik A, Holme I, Nesbakken R, Hatlevoll R, Lindgren M, Brun A, Lindgren S, Notter G, Anderson AP, Eigen K: Combined modality therapy of operated astrocytomas grades III and IV. Confirmation of the value of post-operative irradiation and lack of potentiation of bleomycin on survival time. Cancer 47: 649–652, 1981
Walker MD, Alexander E, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49: 333–343, 1978
Walker MD, Green SB, Byar DP, Alexander E, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, Owens G, Ransohoff J, Robertson JT, Shapiro WR, Smith CB, Strike TA: Randomised comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Eng J Med 303: 1323–1329, 1980
EORTC Brain Tumor Group: Effect of CCNU on survival rate, objective remission and duration of free interval in patients with malignant brain glioma. Final evaluation. Eur J Cancer 14: 851–856, 1978
Chang CH, Horton J, Schoenfeld D, Salazer O, PerezTamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y: Comparison of postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer 52: 997–1007, 1983
EORTC Brain Tumor Group: Evaluation of CCNU, VM-26 plus CCNU and procarbazine in supratentorial brain gliomas. J Neurosurg 55: 27–31, 1981
Edwards MS, Levin VA, Wilson CB: Brain tumor chemotherapy: An evaluation of agents in current use for phase II and III trials. Cancer Treat Rep 64: 1179–1205, 1980
Feun LG, Stewart DJ, Maor M, Leavens M, Savaraj N, Burgess MA, Yung WKA, Benjamin RS: A pilot study of cisdiamminedi-chloropatinum and radiation therapy in patients with high grade astrocytomas. J Neuro-Oncol1: 109–113, 1983
David JS, Milam L, Moshe M, Feun L, Morio L, Jeanne B, Richard C, Loo TL, Robert SB: Human central nervous system distribution of cisdiamminedichloro-platinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 42: 2474–2479, 1982
Recht L, Fram RJ, Strauses G: Preirradiation chemotherapy of supratentorial malignant primary brain tumors with intracarotid cisplatinum and intravenous BCNU. Am J Clin Oncol 13: 125–131, 1990.
Berry RJ: Effect of timing between drugs and radiation on type of interaction. Int J Radiat Oncol Phys 6: 957–959, 1980
Grossman SA, Sheidler VR, Ahn H, Gilbert MR, Wharam M, Bucholtz J: Complete and partial responses of newly diagnosed malignant astrocytomas following continous infusion BCNU and cisplatin. Proc ASCO 8: 88, 1989
Wang HC, Ho YS: Clinicopathological evaluation of 78 astrocytomas in Taiwan with emphasis on simple grading system. J Neuro-Oncol 13: 265–276, 1992
Allen JC, Helson L, Jereb B: Preradiation chemotherapy for newly diagnosed childhood brain tumors. A modified phase II trial. Cancer 52: 2001–2006, 1983
Hochberg FH, Pruitt A, Beck DO, Debrun G, Davis K: The rationale and methodology for intra-arterial chemotherapy with BCNU as treatment for glioblastoma. J Neurosurg 63: 876–880, 1985
Recht L, Fram RJ, Strauss G, Fitzgerald TJ, Liepman M, Lew R, Kadish S, Sherman D, Wilson J, Greenberger J, Egan P, Silver D: Preirradiation chemotherapy of supratentorial malignant primary brain tumors with intracarotid cisplatinum (CDDP) and i.v. BCNU. Am J Clin Oncol 13: 125–131, 1990
Bellamy A, Hill B: Interactions between clinically effective antitumor drugs and radiation in experimental systems. Biochim Biophys Acta 738: 125–166, 1984
Douple EB: Keynote address: Platinum-radiation interactions. NCI Monogr 6: 315–319, 1988
Frei E, Cucchi CA, Rosowsky A: Alkylating agent resistance:in vitro studies with human cell lines. Proc Natl Acad Sci USA 82: 2158–2162, 1985
Alfred Yung WK, Janus TJ, Maor M, Feun LG: Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas. J Neuro-Oncol 12: 131–135, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kiu, M.C., Chang, C.N., Cheng, W.C. et al. Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas. J Neuro-Oncol 25, 215–220 (1995). https://doi.org/10.1007/BF01053154
Issue Date:
DOI: https://doi.org/10.1007/BF01053154